
Regeneron's Livsayis (cemdisiran) gains FDA approval for adults with antibody-positive generalized myasthenia gravis, dosed four times a year.
Click the title above for a link to open the Pharmaceutical Executive December 2023 issue in an interactive PDF format.
almost 3 years ago
Finding that Sparkalmost 3 years ago
Remote Reliance: The Rise of Oncology Home Carealmost 3 years ago
It’s Always Important to Remember: Leaders Make Mistakesalmost 3 years ago
Will Calendar Change Bring an End to Run of Volatility in Biotech?almost 3 years ago
FDA, Industry Face Challenges in the Year Aheadalmost 3 years ago
Navigating the Future: Key Market Access Trends to Watch in ’24almost 3 years ago
Reflecting on 2023





